Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: the FLUniversal consortium. V.M. Cnossen1, P.C.L. Moreira, O.G. Engelhardt, J. Samolej, G.H. Groeneveld, S.P. Jochems W. Huisman, G.K. Pedersen, K. Worzner, L. Recek6, G. Piccini, C.M. Trombetta, A. Aspelund, A. Hoag, M. Reiter, C. Wick, T. Muster, I.M.C. Kamerling. Front Immunol. 2025 May 23:16:1568778. doi: 10.3389/fimmu.2025.1568778. eCollection 2025
FLUNIVERSAL: Rethinking influenza vaccination for a more predictable future. Projects Magazine (2026).
Implementing a Controlled Human Infection Model (CHIM) with a reverse genetics H3N2 (A/Texas/71/2017, clade 3C.3a) influenza challenge virus in healthy volunteers. Victor M. Cnossen, Geert H. Groeneveld, Marissa D. Remeeus, Othmar G. Engelhardt, Jerzy Samolej, Catherine Luke, Marieke L. de Kam, M. van Arkel, Giulia Piccini, Alessandro Manenti, Emanuele Montomoli. Submitted
